Fassina G, Verdoliva A, Palombo G, Ruvo M, Cassani G
TECNOGEN SCpA, Piana di Monte Verna (CE), Italy.
J Mol Recognit. 1998 Winter;11(1-6):128-33. doi: 10.1002/(SICI)1099-1352(199812)11:1/6<128::AID-JMR408>3.0.CO;2-8.
A synthetic ligand [TG19318], able to mimic protein A in the recognition of the immunoglobulin Fc portion, has been previously identified in our laboratory through the synthesis and screening of multimeric combinatorial peptide libraries. In this study we have fully characterized its applicability in affinity chromatography for the downstream processing of antibodies, examining the specificity and selectivity for polyclonal and monoclonal immunoglobulins derived from different sources. Ligand specificity was broader than protein A, since IgG deriving from human, cow, horse, pig, mouse, rat, rabbit, goat and sheep sera, IgY obtained from egg yolk, and IgM, IgA and IgE were efficiently purified on TG19318 affinity columns. Adsorbed antibodies were conveniently eluted by a buffer change to 0.1 M acetic acid or 0.1 M sodium bicarbonate pH 9, with full retention of immunological properties. Monoclonal antibodies deriving from cell culture supernatants or ascitic fluids were also conveniently purified on TG19318 affinity columns, even from very diluted samples. The affinity constant for the TG19318-IgG interaction was 0.3 microM, as determined by optical biosensor measurements. Under optimized conditions, antibody purity after affinity purification was close to 95%, as determined by densitometric scanning of SDS-PAGE gels of purified fractions, and maximal column capacity reached 25 mg Ig/ml support. In vivo toxicity studies in mice indicated a ligand oral toxicity greater than 2000 mg kg-1 while intravenous toxicity was close to 150 mg kg-1. Validation of antibody affinity purification processes for therapeutic use, a very complex, laborious and costly procedure, is going to be simplified by the use of TG19318, which could reduce considerably the presence of biological contaminants in the purified preparation, a very recurrent problem when using recombinant or extractive biomolecules as affinity ligands.
一种能够在识别免疫球蛋白Fc部分时模拟蛋白A的合成配体[TG19318],此前已在我们实验室通过合成和筛选多聚体组合肽库得以鉴定。在本研究中,我们全面表征了其在抗体下游加工的亲和色谱中的适用性,研究了对源自不同来源的多克隆和单克隆免疫球蛋白的特异性和选择性。配体特异性比蛋白A更广,因为源自人、牛、马、猪、小鼠、大鼠、兔、山羊和绵羊血清的IgG、从蛋黄中获得的IgY以及IgM、IgA和IgE都能在TG19318亲和柱上有效纯化。吸附的抗体通过更换为0.1 M乙酸或pH 9的0.1 M碳酸氢钠缓冲液可方便地洗脱,且免疫特性完全保留。源自细胞培养上清液或腹水的单克隆抗体也能在TG19318亲和柱上方便地纯化,即使是从非常稀释的样品中。通过光学生物传感器测量确定,TG19318与IgG相互作用的亲和常数为0.3 microM。在优化条件下,通过对纯化级分的SDS-PAGE凝胶进行光密度扫描测定,亲和纯化后的抗体纯度接近95%,最大柱容量达到25 mg Ig/ml载体。小鼠体内毒性研究表明,该配体的口服毒性大于2000 mg kg-1,而静脉毒性接近150 mg kg-1。治疗用途的抗体亲和纯化过程的验证是一个非常复杂、费力且昂贵的程序,使用TG19318将使其简化,这可以显著减少纯化制剂中生物污染物的存在,而在使用重组或提取的生物分子作为亲和配体时,这是一个非常常见的问题。